[go: up one dir, main page]

WO2025081199A3 - B cell production and expansion - Google Patents

B cell production and expansion

Info

Publication number
WO2025081199A3
WO2025081199A3 PCT/US2024/051471 US2024051471W WO2025081199A3 WO 2025081199 A3 WO2025081199 A3 WO 2025081199A3 US 2024051471 W US2024051471 W US 2024051471W WO 2025081199 A3 WO2025081199 A3 WO 2025081199A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
expansion
cell production
populations
1bbl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/051471
Other languages
French (fr)
Other versions
WO2025081199A8 (en
WO2025081199A2 (en
Inventor
James M. MATHEW
Joseph R. Leventhal
Jes McDaniel SANDERS
Catalina LEE-CHANG
Joshua Levin KATZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of WO2025081199A2 publication Critical patent/WO2025081199A2/en
Publication of WO2025081199A3 publication Critical patent/WO2025081199A3/en
Publication of WO2025081199A8 publication Critical patent/WO2025081199A8/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present disclosure provides methods of producing and expanding populations of B cells (e.g., human B cells for clinical applications). Such expanded populations can be used to produce B cell vaccines containing B cells that express 4-1BBL and are capable of promoting tumor cell death.
PCT/US2024/051471 2023-10-13 2024-10-15 B cell production and expansion Pending WO2025081199A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363590202P 2023-10-13 2023-10-13
US63/590,202 2023-10-13

Publications (3)

Publication Number Publication Date
WO2025081199A2 WO2025081199A2 (en) 2025-04-17
WO2025081199A3 true WO2025081199A3 (en) 2025-07-17
WO2025081199A8 WO2025081199A8 (en) 2025-08-07

Family

ID=95395209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/051471 Pending WO2025081199A2 (en) 2023-10-13 2024-10-15 B cell production and expansion

Country Status (1)

Country Link
WO (1) WO2025081199A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025081199A2 (en) * 2023-10-13 2025-04-17 Northwestern University B cell production and expansion

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176140A1 (en) * 2004-02-10 2005-08-11 Benedict Daniel J. Method and apparatus for cell culture using a two liquid phase bioreactor
US20190352607A1 (en) * 2016-02-16 2019-11-21 Duke University Methods for expanding and differentiating b cells for producing antibody
WO2022040202A1 (en) * 2020-08-17 2022-02-24 Northwestern University B-cell based immunotherapy for the treatment of glioblastoma and other cancers
WO2025081199A2 (en) * 2023-10-13 2025-04-17 Northwestern University B cell production and expansion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176140A1 (en) * 2004-02-10 2005-08-11 Benedict Daniel J. Method and apparatus for cell culture using a two liquid phase bioreactor
US20190352607A1 (en) * 2016-02-16 2019-11-21 Duke University Methods for expanding and differentiating b cells for producing antibody
WO2022040202A1 (en) * 2020-08-17 2022-02-24 Northwestern University B-cell based immunotherapy for the treatment of glioblastoma and other cancers
WO2025081199A2 (en) * 2023-10-13 2025-04-17 Northwestern University B cell production and expansion

Also Published As

Publication number Publication date
WO2025081199A8 (en) 2025-08-07
WO2025081199A2 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
WO2019126634A3 (en) Targeted integration of nucleic acids
AR111785A2 (en) IN VITRO METHOD OF PRODUCTION OF Erythrocytes
WO2025081199A8 (en) B cell production and expansion
MY201926A (en) Biological methods for preparing terpenes
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
EA202091407A1 (en) COMPOSITION OF A SERUM-FREE MEDIUM FOR CELL CULTIVATION AND METHODS OF ITS APPLICATION
WO2005007073A3 (en) Ex vivo progenitor and stem cell expansion for use in the treatment of disease of endodermally-derived organs
BRPI1005683A2 (en) in vitro cell-free process of producing a closed linear deoxyribonucleic acid (dna), kit, method of inducing immunological reaction against an antigen in a host, process of making a pharmaceutical composition and use of a closed linear dna molecule in the manufacture of a medicine
MX2018010529A (en) Compositions and methods for the improved production and delivery of rna by efficient transcription termination.
WO2019002512A3 (en) Engineered and fully-functional customized glycoproteins
WO2014186469A3 (en) Human application of engineered chimeric antigen receptor (car) t-cells
BR112016019677A8 (en) method of preparing an in vitro cell condensate, cell condensate, method of preparing a three-dimensional tissue structure, and gel-like culture support
MX2017007214A (en) Gammadelta t cell expansion procedure.
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
BR112022012109A2 (en) YEAST CELL CAPABLE OF PRODUCING E8,E10-DODECADIENYL COENZYME A AND OPTIONAL E8,E10-DODECADIEN-1-OL, E, METHOD FOR PRODUCING E8,E10-DODECADIENYL COENZYME A AND OPTIONAL E8,E10-DODECADIEN-1-OL IN A YEAST CELL YEAST
WO2021009777A3 (en) Methods of stem cell culture for obtaining products, and implementations thereof
JPWO2018148566A5 (en)
Luo et al. Synthetic genomics: the art of design and synthesis
Galasso et al. Marine polysaccharides, proteins, lipids, and silica for drug delivery systems: A review
AR125461A1 (en) RECOMBINANT ANTIGEN PRESENTING CELLS
WO2005094353A3 (en) Methods for production of regulatory t cells and uses thereof
EP4403648A3 (en) Methods and compositions for manipulating nucleic acids
IL161873A0 (en) Production of cell suspensions
SI1530628T1 (en) Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
WO2004094610A3 (en) Wnt as a factor for cardiac myogenesis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24878255

Country of ref document: EP

Kind code of ref document: A2